GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Q2 FY27 Standalone Net Profit at INR 779.51 Lakhs

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 29 Oct 2026, 10:26 PM IST  ·  BSE ID: 73bf5d4c-a789-43c1-bc26-1df803c579ee
View Original BSE Filing (PDF)
💡
In Simple Terms
Sudarshan Pharma reported higher quarterly profits and revenues, and approved plans to raise significant funds.
🤖 AI Summary
  • Sudarshan Pharma Industries reported standalone Net Profit for Q2 FY27 of INR 779.51 Lakhs, increasing 88.13% YoY.
  • Consolidated Net Profit for the quarter ended 30th September 2026 was INR 762.64 Lakhs, up 82.50% YoY.
  • Standalone Revenue from Operations for Q2 FY27 was INR 20,551.81 Lakhs, a 22.79% increase from Q2 FY26.
  • The Board approved raising funds up to Rs.1,500 crores through Foreign Currency Convertible Bonds (FCCBs) and other securities.
  • A new subsidiary, Sudarshan Chemical Industries Limited, was incorporated effective 5th June 2026 for manufacturing chemicals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Net Profit (Q2 FY27)
INR 779.51 Lakhs
88.13%
Consolidated Net Profit (Q2 FY27)
INR 762.64 Lakhs
82.50%
Standalone Revenue from Operations (Q2 FY27)
INR 20,551.81 Lakhs
22.79%
Approved Fund Raising Limit
Rs. 1,500 crores
🏢 How This Affects the Company
📈
Business Impact
The incorporation of a new subsidiary, Sudarshan Chemical Industries Limited, indicates an expansion into manufacturing chemicals and allied goods, potentially diversifying revenue streams. The increase in revenue from operations suggests stronger sales performance.
💰
Financial Impact
Standalone net profit for the quarter increased significantly to INR 779.51 Lakhs. The approval to raise up to Rs. 1,500 crores through FCCBs and other securities provides substantial capital for future growth initiatives or debt refinancing.
⚙️
Operational Impact
Establishing a new subsidiary for chemical manufacturing suggests an expansion of operational scope and potential for increased production capacity in a new segment. This also indicates strategic intent towards vertical integration or market expansion.
⚠️
Risk Impact
Raising funds through FCCBs introduces conversion risk related to equity dilution for existing shareholders if the bonds are converted. The significant increase in borrowings by INR 11,600.25 Lakhs non-current and INR -465.08 Lakhs current quarter-over-quarter indicates a higher leverage profile for the company.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All existing shareholders are affected by the improved financial performance and the future capital structure changes from the approved fund-raising of up to Rs. 1,500 crores via FCCBs and other securities.
🔍
Management Signal
Management is signaling a focus on growth, evidenced by the improved financial results, the strategic incorporation of a new subsidiary, and the approval for substantial fund-raising.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess sustained profit and revenue growth.
Updates on FCCB issuance — details on terms and utilization of funds.
Progress of new subsidiary, Sudarshan Chemical Industries Limited — operational commencement.
MEDIUM RISK Significant increase in borrowings and potential equity dilution from FCCBs introduce financial and ownership risks.
💡 Investor Takeaway
Sudarshan Pharma Industries reported Q2 FY27 standalone net profit of INR 779.51 Lakhs, an 88.13% YoY increase, and consolidated net profit of INR 762.64 Lakhs, up 82.50% YoY. Revenue from operations increased by 22.79% to INR 20,551.81 Lakhs. The Board approved fund-raising up to Rs. 1,500 crores.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Net Profit for Q2 FY27 increased to INR 779.51 Lakhs, a 88.13% rise from INR 414.03 Lakhs in Q2 FY26.
  • Standalone Revenue from Operations for Q2 FY27 grew to INR 20,551.81 Lakhs, up 22.79% from INR 16,738.63 Lakhs in Q2 FY26.

⚠️ Concerns

  • Non-current borrowings increased from INR 3,039.26 Lakhs in March 2026 to INR 14,639.51 Lakhs in September 2026.
  • Standalone cash and cash equivalents significantly decreased from INR 10.90 Lakhs as of March 31, 2026, to INR 64.92 Lakhs as of September 30, 2026, on a half-yearly basis (from 5,240.44 Lakhs profit before working capital changes for H1 FY26 to 4350.05 Lakhs profit before working capital changes for H1 FY27).
📅 Company Track Record
Sudarshan Pharma Industries resubmitted its FY26 results on June 4, 2026, confirming a Net Profit After Tax of Rs. 978.50 lakhs, and released its first audited FY26 financial statements on April 30, 2026, following listing regulations.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Sudarshan Pharma Industries' standalone net profit for Q2 FY27?
Sudarshan Pharma Industries reported a standalone net profit of INR 779.51 Lakhs for the quarter ended 30th September 2026, an 88.13% increase compared to INR 414.03 Lakhs in Q2 FY26.
What was Sudarshan Pharma Industries' consolidated net profit for Q2 FY27?
The consolidated net profit for Sudarshan Pharma Industries for the quarter ended 30th September 2026 was INR 762.64 Lakhs, showing an 82.50% increase from INR 417.88 Lakhs in Q2 FY26.
What is Sudarshan Pharma Industries' revenue from operations for Q2 FY27?
Sudarshan Pharma Industries' standalone revenue from operations for Q2 FY27 was INR 20,551.81 Lakhs, which is a 22.79% increase from INR 16,738.63 Lakhs reported in Q2 FY26.
What is the approved fund-raising limit for Sudarshan Pharma Industries?
The Board of Directors approved raising funds up to Rs. 1,500 crores through Foreign Currency Convertible Bonds (FCCBs) and other securities.
Did Sudarshan Pharma Industries incorporate any new subsidiaries?
Yes, Sudarshan Pharma Industries incorporated a new subsidiary, Sudarshan Chemical Industries Limited, effective 5th June 2026, for manufacturing chemicals, organic and inorganic compounds, and other allied goods.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.